Importantly, introducing wild-type MTSS1 or a mutated non-degradable MTSS1 (MTSS1/S322A) into breast or prostate cancer cells with low wild-type MTSS1 expression significantly inhibited cellular proliferation and migration. Here, MTSS1 is linked to prostate carcinoma.